Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Peginterferon alfa

Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK (2001) Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C a randomised trial. Lancet 358 958-965... [Pg.23]

Forestier N, Reesink HW, Weegink CJ, McNair L, Kieffer TL, Chu HM, Purdy S, Jansen PL, Zeuzem S (2007) Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C. Hepatology 46 640-648... [Pg.104]

Jacobson IM, Everson GT, Gordon SC, Kauffman R, McNair L, Muir A, McHutchison JG (2007) Interim analysis results from a phase 2 study of telaprevir with peginterferon alfa-2A and ribavirin in treatment-naive subjects with hepatitis C. AASLD 58th Annual Meet, Abstract 177 Johnson M (2006) Response to Atazanavir/ritonavir versus lopinavir/ritonavir equivalent or different efficacy profiles by HUl. AIDS 20 1987... [Pg.105]

Fried MW, Shiftman ML, Reddy KR, Smith C, Marinos G, Goncales EL Jr, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J (2002) Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347 975-982... [Pg.233]

Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lai MY, Gane E, O Grady J, Reichen J, Diago M, Lin A, Hoffman J, Brunda Ml (2000) Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 343(23) 1666-1672... [Pg.346]

Zeuzem S, Hultcrantz R, Bourliere M, Goeser T, Marcellin P, Sanchez-Tapias J, Sarrazin C, Harvey J, Brass C, Albrecht J (2004) Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 40(6) 993-999... [Pg.346]

Zeuzem S, Buti M, Ferenci P, Sped J, Horsmans Y, Cianciara J, Ibranyi E, Weiland O, NovieUo S, Brass C, Albrecht J (2006) Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 44(1) 97-103... [Pg.346]

Chronic HCV- In combination with peginterferon alfa-2a for the treatment of adults with chronic HCV infection who have compensated liver disease and have not been previously treated with interferon alpha. Patients in whom efficacy was demonstrated included patients with compensated liver disease and histological evidence of cirrhosis (Child-Pugh class A). [Pg.1772]

The safety and efficacy of ribavirin capsules or oral solution with interferons other than interferon alfa-2b or peginterferon alfa-2b products have not been established. [Pg.1772]

Peginterferon alfa-2a and Ribavirin Tabiet Dosing Recommendations... [Pg.1772]

Capsules/Oral solution When given in combination with peginterferon alfa-2b, it is... [Pg.1773]

Ribavirin capsuies/Peginterferon alfa-2b combination therapy (adults) - The recommended dose of ribavirin capsules is 800 mg/day in 2 divided doses 2 capsules (400 mg) in the morning with food and 2 capsules (400 mg) in the evening with food. [Pg.1775]

Ribavirin tablets/Peginterferon alfa-2a Ribavirin tablets/peginterferon alfa-2a combination therapy is contraindicated in patients with autoimmune hepatitis and... [Pg.1777]

Capsules/Tablets/Oral solution - Ribavirin monotherapy is not effective for the treatment of chronic HCV infection. The safety and efficacy of ribavirin capsules and oral solution have only been established when used together with interferon alfa-2b, recombinant as interferon alfa-2b/ribavirin capsule combination therapy or with peginterferon alfa-2b injection. [Pg.1778]

Capsules/Tablets/Oral solution-There are significant adverse events caused by ribavirin capsules/interferon alfa-2b or peginterferon alfa-2b therapy, and ribavirin tablets/peginterferon alfa-2a therapy, including severe depression and suicidal ideation, hemolytic anemia, suppression of bone marrow function, autoimmune and infectious disorders, pulmonary dysfunction, pancreatitis, and diabetes. [Pg.1778]

Pancreatitis Suspend ribavirin, interferon alfa-2b, peginterferon alfa-2b, or peginterferon alfa-2a therapy in patients with signs and symptoms of pancreatitis and discontinue in patients with confirmed pancreatitis. [Pg.1779]

Capsules/Oral solution - Suicidal ideation or attempts occurred more frequently among pediatric patients, primarily adolescents, compared with adult patients during treatment and off-therapy follow-up. Safety and efficacy of ribavirin in combination with peginterferon alfa-2b has not been established in pediatric patients. [Pg.1781]

Alpha interferons, including peginterferon alfa-2a, may cause or aggravate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, and infectious disorders. [Pg.1980]

Closely monitor patients with periodic clinical and laboratory evaluations. Patients with persistently severe or worsening signs or symptoms of these conditions should be withdrawn from therapy. In many, but not all cases, these disorders resolve after stopping peginterferon alfa-2a (see Warnings and Adverse Reactions). [Pg.1981]

Chronic hepatitis C monoinfection The recommended dose of peginterferon alfa-2a is 180 meg (1 ml or 0.5 ml prefilled syringe) once weekly for 48 weeks by subcutaneous administration in the abdomen or thigh. [Pg.1981]

A patient should self-inject peginterferon alfa-2a only if the physician determines that it is appropriate, the patient agrees to medical follow-up as necessary, and training in proper injection technique has been provided. [Pg.1981]

Peginterferon alfa-2a/Ribavirin tablet combination The recommended dose of peginterferon alfa-2a when used in combination with ribavirin tablets is 180 meg (1 mL vial or 0.5 mL prefilled syringe) subcutaneously once weekly. The recommended dose of ribavirin and duration for the peginterferon alfa-2a/ribavirin tablet combination therapy is based on viral genotype. [Pg.1981]

Peginterferon alfa-2a Dose reduction to 135 meg peginterferon alfa-2a is recommended if the neutrophil count is less than 750 cells/mm. For patients with absolute neutrophil count (ANC) values below 500 cells/mm, suspend treatment until ANC values return to more than 1000 cells/mm. Initially reinstitute therapy at 90 meg peginterferon alfa-2a, and monitor the neutrophil count. [Pg.1982]

Dose reduction to 90 meg peginterferon alfa-2a is recommended if the platelet count is less than 50,000 cells/mm. Cessation of therapy is recommended when platelet count is below 25,000 cells/mm. ... [Pg.1982]

Guidelines for Modification or Discontinuation of Peginterferon alfa-2a and for Scheduling Visits for Patients with Depression... [Pg.1983]

Combination therapy with ribavirin tabiets-The recommended dose when used in combination with ribavirin tablets is peginterferon alfa-2a 180 meg subcutaneously once weekly and oral ribavirin tablets 800 mg daily given in 2 divided doses for a total of 48 weeks, regardless of genotype. Because ribavirin absorption increases when administered with a meal, patients are advised to take ribavirin with food. [Pg.1984]

Peginterferon Alfa-2a Hematological Dose Modification Guidelines... [Pg.1985]

See other pages where Peginterferon alfa is mentioned: [Pg.233]    [Pg.236]    [Pg.237]    [Pg.237]    [Pg.237]    [Pg.240]    [Pg.240]    [Pg.329]    [Pg.341]    [Pg.341]    [Pg.342]    [Pg.343]    [Pg.344]    [Pg.344]    [Pg.345]    [Pg.1773]    [Pg.1980]    [Pg.1985]   
See also in sourсe #XX -- [ Pg.2 , Pg.945 , Pg.946 ]

See also in sourсe #XX -- [ Pg.2 , Pg.205 ]

See also in sourсe #XX -- [ Pg.2 , Pg.550 ]

See also in sourсe #XX -- [ Pg.2 , Pg.815 ]



SEARCH



Interferon Peginterferon alfa

PEGASYS (peginterferon alfa

Peginterferon

Peginterferon alfa for hepatitis

Peginterferon alfa-2a

Ribavirin Peginterferon alfa

© 2024 chempedia.info